RayKnowChina Research Map
Shortlist0

RecruitingEwing sarcomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

An open trial on Ewing sarcoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Children's Hospital首都医科大学附属北京儿童医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06564272, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 12 years to 18 years; sex: all

    Registered eligibility fields

  2. Currently participating in another therapeutic clinical trial; received any anticancer treatment within 2 weeks or 5 half-lives (whichever is longer) before the start of the study treatment; received whole-brain radiation therapy within 14 days before the start of the study treatment; received stereotactic radiosurgery within 7 days before the start of the study treatment; or received herbal or traditional Chinese medicine for anticancer purposes within 2 weeks before the study treatment;

    Exclusion criterion 7

    Persistent toxicity from previous anticancer treatment that has not improved to ≤ Grade 1 (according to CTCAE v5.0), excluding alopecia;

    Exclusion criterion 9

  3. Karnofsky performance status (≥16 years) or Lansky performance status (<16 years) score of ≥60%;

    Inclusion criterion 5

  4. Patients with at least one measurable lesions according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors);

    Inclusion criterion 6

  5. History of or concurrent other malignancies within the past 5 years;

    Exclusion criterion 3

    Hepatitis B surface antigen (HBsAg) positive with HBV-DNA ≥500 IU/mL or 2500 copies/mL; Hepatitis C virus (HCV) antibody positive with HCV RNA ≥200 IU/mL or positive test results; HIV-positive individuals;

    Exclusion criterion 13

  6. Female patients who have started menstruating must have a negative pregnancy test;

    Inclusion criterion 9

    Fertile patients (e.g., females who have started menstruating or males who have started ejaculating) who do not agree to use contraception (e.g., birth control pills or condoms) during the study and for 6 months after the study ends;

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06564272, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age between 12 and less than 18 years;
  • Diagnosed with Ewing sarcoma confirmed by histopathological examination;
  • Patients with locally advanced or metastatic Ewing sarcoma that is unresectable or has failed standard treatment, and for whom no other treatment options are available as assessed by the investigator;
  • Body weight of ≥30 kg;
  • Karnofsky performance status (≥16 years) or Lansky performance status (<16 years) score of ≥60%;
  • Patients with at least one measurable lesions according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors);
  • Expected survival of more than 12 weeks;
  • Sufficient organ and bone marrow function;
  • Female patients who have started menstruating must have a negative pregnancy test;
  • The patient and their legal guardians understand and are willing to participate in the trial, and have signed the informed consent form.

Exclusion Criteria:

  • Patients with primary central nervous system tumors;
  • Presence of central nervous system metastases as diagnosed by imaging;
  • History of or concurrent other malignancies within the past 5 years;
  • Gastrointestinal abnormalities;
  • Cardiovascular or cerebrovascular abnormalities;
  • Patients who have previously received VEGFR-TKI small molecule treatment;
  • Currently participating in another therapeutic clinical trial; received any anticancer treatment within 2 weeks or 5 half-lives (whichever is longer) before the start of the study treatment; received whole-brain radiation therapy within 14 days before the start of the study treatment; received stereotactic radiosurgery within 7 days before the start of the study treatment; or received herbal or traditional Chinese medicine for anticancer purposes within 2 weeks before the study treatment;
  • Underwent major surgery within 2 months before enrollment or have not fully recovered, or plan to undergo surgery during the current study period;
  • Persistent toxicity from previous anticancer treatment that has not improved to ≤ Grade 1 (according to CTCAE v5.0), excluding alopecia;
  • Unhealed skin wounds, surgical sites, traumatic sites, severe mucosal ulcers, or fractures;
  • Uncontrolled significant pleural effusion, ascites, or pericardial effusion;
  • Active bacterial, viral, or fungal infections; unexplained fever >38.5°C within 2 weeks before enrollment;
  • Hepatitis B surface antigen (HBsAg) positive with HBV-DNA ≥500 IU/mL or 2500 copies/mL; Hepatitis C virus (HCV) antibody positive with HCV RNA ≥200 IU/mL or positive test results; HIV-positive individuals;
  • Presence of psychiatric or neurological disorders; or cognitive impairment;
  • Fertile patients (e.g., females who have started menstruating or males who have started ejaculating) who do not agree to use contraception (e.g., birth control pills or condoms) during the study and for 6 months after the study ends;
  • Patients with insufficient compliance as evaluated by investigator;
  • The investigator believes that it is not suitable to patient in this clinical trial.

Quoted from ClinicalTrials.gov, NCT06564272, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06564272, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06564272